Navigation Links
Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis
Date:11/6/2011

EAST HANOVER, N.J., Nov. 7, 2011 /PRNewswire/ -- Novartis announced today new pivotal Phase III data showing 45% of children with active systemic juvenile idiopathic arthritis (SJIA) were able to substantially reduce their use of oral corticosteroids (often described as steroids) within 28 weeks of commencing treatment with ACZ885 (canakinumab) (p<0.0001)[1].

The results of the study, which met both primary endpoints, will be presented on November 9th at the American College of Rheumatology's (ACR) Annual Scientific Meeting in Chicago, US[1].

"The treatment of SJIA is a challenge given our current treatment options. Despite our best efforts, optimal disease control is often times elusive. We still must use steroids in the treatment of these children with SJIA. Steroids help manage many SJIA symptoms, such as fever and inflammation, but doctors try to minimize their use because of the potential negative impact on bones and growth," said Daniel Lovell, M.D., one of the study investigators and Professor of Pediatrics at the Cincinnati Children's Hospital Medical Center. "These data are exciting because they show that patients on ACZ885 were able to reduce their steroid use, and also experienced excellent disease control."

In addition, patients with SJIA on ACZ885 were nearly three times (0.37 hazard ratio) less likely to suffer a new flare. Therefore, only 27% of ACZ885-treated patients experienced a new flare, vs. 75% of patients on placebo during the study (p=0.0043)[1].

Data from this trial supports the safety and efficacy profile of ACZ885 in the study population. These results, along with data from a second pivotal study, are planned to form the basis for worldwide regulatory submissions in 2012. Side effects observed in this study were similar to those already seen for ACZ885's approved indication, including infections and neutropenia[1]. In addition, cases of macrophage activation syndrome (MAS) were reported in this study[1]
'/>"/>

SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
2. Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe
3. Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
4. Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
5. Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US
6. Novartis/Schering-Ploughs Drug Will Replace AstraZenecas Symbicort as Decision Resources Clinical Gold Standard by 2012 for the Treatment of Asthma
7. Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD
8. Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure
9. Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target
10. Novartis Class Awarded $250 Million in Punitive Damages
11. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... 2014 Kamal Rashid , PhD, ... and Training Center (BETC) and research professor of biology ... 2014 , an international two-day event focused on biomanufacturing ... Global Summits, the event will bring together leaders of ... to develop and produce human therapeutics. “The growth curve ...
(Date:9/23/2014)... VA (PRWEB) September 23, 2014 ATCC, ... is pleased to announce two important appointments to the ... Executive Vice President of Strategy and Technology and Dr. ... for the Standards Resource Center. Both roles are new ... H. Cypess, President and CEO at ATCC described the ...
(Date:9/23/2014)... Sept. 23, 2014  Age Defying Dermatology ® , ... has become one of the first clinics in the ... aesthetic laser for tattoo removal. The treatment safely and ... "For years, tattoo removal has been a lengthy, painful, ... "This is an opportunity to erase tattoo pigment more ...
(Date:9/23/2014)... 23, 2014   GenoSpace , a precision medicine ... tools to enable the broad use of genomic data ... has been awarded Phase I of a Fast Track ... Institutes of Health (NIH) to enable enhanced data access ... http://photos.prnewswire.com/prnh/20140922/147649 During the past ...
Breaking Biology Technology:Worcester Polytechnic Institute's Biomanufacturing Expertise to be Featured in Berlin 2Worcester Polytechnic Institute's Biomanufacturing Expertise to be Featured in Berlin 3ATCC Announces New Appointments to its Leadership Team 2ATCC Announces New Appointments to its Leadership Team 3Age Defy Now Offers World's Most Advanced Technology for Tattoo Removal 2GenoSpace Awarded Fast Track SBIR Grant to Enable Data Access and Cohort Construction for Biorepositories 2
... BOCA RATON, Fla., Oct. 30 Nabi,Biopharmaceuticals (Nasdaq: ... Group (ISS) and Glass Lewis & Co., two ... that stockholders of the,Company vote "FOR" the Company,s ... certain Corporate Shared Services assets to Biotest,Pharmaceuticals Corporation, ...
... (OTC,Bulletin Board: NNLX) a nano-biotechnology company announces the date ... meeting will take place at 1 PM on 12/28/07 ... A call-in number will be provided for,questions to management. ... days prior to the meeting. Shareholders of record as ...
... 30 /PRNewswire-FirstCall/ - ICBS Limited,(PINKSHEETS: ICBM), today announced ... Bacteria Bank Ltd., is a Bio medical ... for use in medical research, located,in Montreal Canada. ... a world,renowned bacteriologist. Dr. Karl Weiss is ...
Cached Biology Technology:RiskMetrics Group (ISS) and Glass Lewis & Co. Support Nabi Biopharmaceuticals' Proposed Asset Sale 2RiskMetrics Group (ISS) and Glass Lewis & Co. Support Nabi Biopharmaceuticals' Proposed Asset Sale 3NanoLogix Inc. Sets Date for Annual Shareholder Meeting and Provides Shareholder Update 2NanoLogix Inc. Sets Date for Annual Shareholder Meeting and Provides Shareholder Update 3ICBS acquires 30% interest in Bacteria Bank Ltd. 2
(Date:9/23/2014)... body forms new tissues during the healing process, ... other. For years, scientists believed this communication happened ... Mellon University and the University of Pittsburgh have ... is equally if not more crucial. The findings, ... Proceedings of the National Academy of Sciences , ...
(Date:9/23/2014)... Research by Rice University scientists who are fighting a ... be a clinician,s most powerful ally. , "Recent research ... cyberwarfare against the immune system, and we studied the ... how we might turn the tables on cancer," said ... this week in the Early Edition of the ...
(Date:9/23/2014)... identified a gene mutation that causes aplastic anemia, ... marrow fails to produce normal amounts of blood ... had blood disorders, the researchers discovered a defect ... with crucial roles in normal cell function. , ... molecular-based treatments that bypass the gene defect and ...
Breaking Biology News(10 mins):The mechanics of tissue growth 2Immune system is key ally in cyberwar against cancer 2Immune system is key ally in cyberwar against cancer 3Gene mutation discovered in blood disorder 2
... Holy Grails of nanotechnology, but nature has been producing ... scientists has taken a unique look at how thousands ... clusters that direct cell movement to select chemicals in ... complex periodic patterns in biological systems can be generated ...
... Alexopoulos Prize will be given to Dr. Brian Shaw, Texas ... 29 in Snowbird, Utah. The honor based on ... known as the Outstanding Early-Career Mycologist Award of the Mycological ... and four review papers in 12 years. Both the National ...
... This release is available in Spanish . ... technique consisting of the induction of neuronal degeneration neuronal for ... helpful for the study of retinitis pigmentosa (RP), a group ... than one million persons a year all over the world. ...
Cached Biology News:Spontaneous assembly 2Spontaneous assembly 3Spontaneous assembly 4Work in mice will contribute to the study of hereditary diseases that lead to blindness 2
...
... Continuing a tradition of progressive centrifuge design ... series. The Centra-CL3 and Centra-CL3R (refrigerated) general ... laboratory., Quality Control Over Sample Preparation ... lock up to 99 protocols and has ...
PP2B-Abeta (C-20)...
... 8-iso PGE2 is one of several isoprostanes ... is a potent renal vasoconstrictor in the rat. ... with IC50 values of 0.5 and 5 µM, ... the rat at a concentration of 4 mg/kg/min, ...
Biology Products: